Latest Commercialization News

AVITA Medical reported a 13% drop in Q3 commercial revenue to $17.1 million but improved its net loss and secured CE Mark approval for RECELL GO in Europe, signaling strategic shifts ahead.

MedAdvisor Limited has appointed John Ciccio as its new CEO and Managing Director, marking a strategic leadership shift aimed at capitalising on recent technology advancements and US market growth.

hummgroup and The Abercrombie Group have mutually agreed to end discussions on an unsolicited acquisition proposal, with TAG withdrawing its offer that included a 35% premium. The Independent Board Committee now shifts focus to operational execution and shareholder value.

The GPT Group has reported robust occupancy and sales growth across its property portfolios for the September quarter 2025, prompting an upgrade to its full-year earnings guidance.

Proteomics International secures half a million dollars from the Western Australian Government to accelerate commercialisation of PromarkerEndo, a groundbreaking blood test for early endometriosis diagnosis.

Chimeric Therapeutics has responded to ASX inquiries regarding the disclosure timing and materiality of new clinical data from its ADVENT-AML trial, emphasizing compliance with continuous disclosure rules and the careful verification of promising patient responses.

Seven West Media reports a 6% EBITDA rise in H2 FY25 driven by TV and digital growth, while announcing a transformative merger with Southern Cross Media.

Bubs Australia Limited announces it expects to recover A$825,000 from Willis Trading Limited’s secured creditor following arbitration proceedings, while no further recoveries are anticipated from related parties.

Neuren Pharmaceuticals reported a milestone quarter with DAYBUE net sales reaching US$101.1 million, driving a 24% jump in royalty income. The expanding patient base and community physician uptake signal strong growth ahead.

Monash University has secured a $799,866 Australian Research Council grant to study brain injury thresholds using HITIQ’s PROTEQT™ instrumented mouthguards, with a $200,000 pre-order confirming commercial momentum.

ABx Group has achieved over 98% retention of rare earth elements with near-complete impurity removal in large batch tests from its Deep Leads project, advancing toward delivering its first mixed rare earth carbonate sample by November’s end.

Marquee Resources has entered a non-exclusive collaboration with Chinese metallurgical leader Yantai Jinao to advance testwork and commercial pathways for its Mount Clement Antimony Project in Western Australia.